Filing Flows › Journey Medical (DERM) › Q4 2024
Journey Medical (DERM) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
Journey Medical (DERM) reported revenue of $13.6M for the fourth quarter 2024 (Q4 2024), -11% from a year earlier and -7% from the quarter before. Operating margin was 16.4%, net earnings $1.5M (11.2% of revenue).
Journey Medical, Q4 2024: revenue $13.6M (-11% year over year), operating margin 16.4%, net earnings $1.5M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.6M | -7% | -11% |
| Operating profit | $2.2M | — | — |
| Net earnings | $1.5M | — | — |
| Operating cash flow | $2.2M | — | — |
What changed
Revenue was $13.6M in Q4 2024, down 11% year over year and down 7% from the previous quarter. Qbrexza was the largest line at 42% of revenue.
Operating profit was $2.2M, a 16.4% margin (up 30.2 points year over year). Total costs fell 34% while revenue fell 11%. Net earnings were $1.5M. The effective tax rate was 3.9%.
Operating cash flow was $2.2M, 146% of net earnings. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $674K.
Questions
What was Journey Medical's revenue in the fourth quarter 2024?
Journey Medical (DERM) reported revenue of $13.6M for the fourth quarter 2024 (Q4 2024), -11% from a year earlier and -7% from the quarter before.
Was Journey Medical profitable in the fourth quarter 2024?
Operating profit was $2.2M (16.4% of revenue) and net earnings $1.5M.
Source: Journey Medical 10-K on SEC EDGAR.